Effects of ICD implantation on quality-adjusted life years in patients with congestive heart failure

被引:4
作者
Ozasa, Neiko [2 ]
Morimoto, Takeshi [1 ]
Furukawa, Yutaka [2 ]
Shizuta, Satoshi [2 ]
Nishiyama, Kei [2 ]
Kita, Toru [2 ]
Kimura, Takeshi [2 ]
机构
[1] Kyoto Univ, Grad Sch Med, Ctr Med Educ, Sakyo Ku, Kyoto 6068501, Japan
[2] Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Kyoto 6068507, Japan
关键词
decision analysis; implantable cardioverter-defibrillator; primary prevention; quality-adjusted life years; reduced left ventricular ejection fraction;
D O I
10.1016/j.ijcard.2006.11.216
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Effects of prophylactic implantable cardioverter-defibrillator (ICD) on quality-adjusted life years (QALYs) in patients with congestive heart failure are uncertain. Methods: We developed a decision model for patients at risk of sudden death due to reduced ejection fraction and who had no history of life-threatening ventricular arrhythmias. It estimated the QALYs for ICD strategy as a primary prevention for sudden cardiac death and conventional strategy without antiarrhythmic therapies. Results: In a 3-year time period, the QALYs for patients with conventional strategy were higher than that of ICD strategy (2.19 years vs. 2.14 years). When the mortality rate of conventional strategy exceeded 8.6%/year and the hazard ratio of death for the ICD strategy was lower than 0.70, the ICD strategy was the superior treatment option. Conclusions: The QALYs of patients with ICD could be lower than that of conventional strategy. Incorporating quality of life could affect decision making of ICD implantation. (c) 2007 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:213 / 216
页数:4
相关论文
共 12 条
  • [1] Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients
    Alter, P
    Waldhans, S
    Plachta, E
    Moosdorf, R
    Grimm, W
    [J]. PACE-PACING AND CLINICAL ELECTROPHYSIOLOGY, 2005, 28 (09): : 926 - 932
  • [2] Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure
    Bardy, GH
    Lee, KL
    Mark, DB
    Poole, JE
    Packer, DL
    Boineau, R
    Domanski, M
    Troutman, C
    Anderson, J
    Johnson, G
    McNulty, SE
    Clapp-Channing, N
    Davidson-Ray, LD
    Fraulo, ES
    Fishbein, DP
    Luceri, RM
    Ip, JH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (03) : 225 - 237
  • [3] Implantable cardioverter-defibrillators
    DiMarco, JP
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (19) : 1836 - 1847
  • [4] Gregoratos Gabriel, 2002, Circulation, V106, P2145, DOI 10.1161/01.CIR.0000035996.46455.09
  • [5] Patient preferences for heart failure treatment: Utilities are valid measures of health-related quality of life in heart failure
    Havranek, EP
    McGovern, KM
    Weinberger, J
    Brocato, A
    Lowes, BD
    Abraham, WT
    [J]. JOURNAL OF CARDIAC FAILURE, 1999, 5 (02) : 85 - 91
  • [6] Medical progress: Heart failure
    Jessup, M
    Brozena, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (20) : 2007 - 2018
  • [7] Preferences for quality of life or survival expressed by patients with heart failure
    Lewis, EF
    Johnson, PA
    Johnson, W
    Collins, C
    Griffin, L
    Stevenson, LW
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2001, 20 (09) : 1016 - 1024
  • [8] Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors:: the CHARM-Added trial
    McMurray, JJV
    Östergren, J
    Swedberg, K
    Granger, CB
    Held, P
    Michelson, EL
    Olofsson, B
    Yusuf, S
    Pfeffer, MA
    [J]. LANCET, 2003, 362 (9386) : 767 - 771
  • [9] Optimal strategy for the first episode of primary spontaneous pneumothorax in young men - A decision analysis
    Morimoto, T
    Fukui, T
    Koyama, H
    Noguchi, Y
    Shimbo, T
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 2002, 17 (03) : 193 - 202
  • [10] Morimoto Takeshi, 2002, J Epidemiol, V12, P160